glp-1 receptor agonist and dpp-4 inhibitor combination contraindicated Clinical Focus on Agonists in Type 2 Diabetes Mellitus GLP-1 receptor agonist versus DPP-4

Zoungas, S

le Roux 2 , Adie Viljoen 1 Endocrinology and Metabolism 2024;39(1):12-22

Recent advances in TfR-targeting platforms have substantially improved CNS distribution, enabling the approval of two BBB-penetrant enzyme replacement therapies for Hunter syndrome

SA-treated animals also had increased colonic EKR1/2 and prohormone convertase 1/3 proteins (PC1/3) protein phosphorylation

In the coming weeks, Novo Nordisk is expected to release fresh Phase III data for its next-generation weight loss treatment CagriSema, which analysts say could be the next big thing in the obesity space

An experienced attorney can help in maximizing compensation